This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Current perspectives on pyospermia: a review
Srinivas Pentyala1,2, Jacky
Lee2, Sandeep Annam1, Julio
Alvarez1, Amulya Veerraju1, Naveen
Yadlapalli1, S. Ali Khan2
Departments of 1Anesthesiology and
2Urology, School of Medicine, State University of New York, Stony Brook, New York
11794, USA
Abstract
Pyospermia is an abnormal laboratory finding of high concentration of white blood cells in human ejaculates
during infertility workup. The role of pyospermia and its impact on fertility is an important consideration in the
management of infertility. Etiology, pathogenesis, diagnostic modalities and the management of pyospermia are
reviewed in this paper. Current use of antibiotics and the intrinsic production of antioxidants in the management of
pyospermia are also discussed in this review. (Asian J Androl 2007 Sep; 9: 593_600)
Keywords: pyospermia; semen; leukocytes; ejaculate; infertility
Correspondence to: Srinivas Pentyala, PhD, Department of Anesthesiology, State University of New York, Stony Brook, New York 11794,
USA.
Tel: +1-631-444-2974 Fax: +1-631-444-2907
E-mail: Srinivas.pentyala@stonybrook.edu
Received 2006-02-28 Accepted 2006-11-09
DOI: 10.1111/j.1745-7262.2007.00251.x
1 Introduction
Pyospermia is a laboratory finding categorized as the abnormal presence of leukocytes in human ejaculates. It is
presumed to be a clinical sign of infection/inflammation of the accessory sex organs or of the lower genito-urinary
tract [1_3]. Numerous studies demonstrated that these leukocytes present in ejaculates have a physiological effect on
sperm functions, which may further implicate male infertility
[4_7]. Berger et al. [8] suggested that the presence of
leukocytes in seminal fluid ejaculate would be the best indicator of an atypical sperm penetration assay (SPA) in
normal semen analysis. Studies by Maruyama et
al. [9] reported decreased fertilizing ability of the donors' sperms
after adding the supernatant of white blood cells (WBCs)
to a fertile donors' semen.
Wolff et al. [7] demonstrated a strong inverse relationship between major seminal fluid parameters and
symptomatic pyospermia. The seminal fluid parameters currently studied
include: total sperm count, percent motility and morphology, sperm velocity, presence of fructose and the total number of motile
sperm. If the semen analysis contains more than
106/mL of WBCs, microbiological evaluations such as the culture of urine and ejaculates are
essential to determine if accessory sex gland and lower urinary tract infections are present.
Current diagnostic modalities on determining the concentrations of WBCs in semen focus on sperm functions. The
impact of leukocytes depends upon the stages and sites at which WBCs enter the semen, the involvement of specific
types and concentrations of leukocytes, and their states of activation. Berger
et al. [8] showed that the presence of one neutrophil in a pool of 100 sperms is sufficient to increase the risk of an abnormal SPA by a factor of 8.17. However,
studies on temporal morphology, transition of leukocytes and its relationship to sperm parameters are still in the early
stage and are not being routinely used in laboratory diagnosis of pyospermia because of such factors as time and cost.
2 Historical perspectives
Pyospermia is established when the concentration of
seminal WBCs is in the range between
5×105/mL and 5×106/mL of seminal fluid during semen analysis
[10]. Pyospermia is also defined when more than 1 000 000
WBCs are counted in 1 mL of semen [11].
Shy et al. [12] suggested that pyospermia is present when six or
more WBCs are present among 100 spermatozoa.
The World Health Organization (WHO) internationally
standardizes and defines pyospermia as
1×106 WBCs/mL semen as diagnosed by measuring either peroxidase or by
immunohistological detection methods [13]. This is
currently the universally accepted definition of pyospermia.
It establishes a universal guideline to determine the
number of WBCs in semen that may have an impact on male
fertility.
Historically, the laboratory discrepancies of WBC
count in semen can be explained by recent discoveries
of variable types of immature germ cells that are wrongly
identified as WBCs [14]. These immature cells closely
resemble WBCs in size, morphology and the diverse WBC
types distinguished by different laboratory methods.
When pyospermia is present, the determination of the
actual concentration of WBCs in semen will be difficult
because of the erroneous presence of WBCs [14].
"Pseudo-pyospermia" is the clinical terminology applied
when diagnosis of "pyospermia" is mistaken by the
presence of immature germ cells, rather than the actual WBCs
in semen. Fortunately, special immunohistochemical
staining can differentiate immature germ cells from WBCs
and can establish an accurate leukocyte count in SPA
[14]. This staining technique is mainly time consuming
and expensive, and hence cannot be routinely used
during semen analysis for the diagnosis of pyospermia.
3 Etiology
Pyospermia has multifactorial causes, including
infection, inflammation and autoimmunity [2]. The
etiology can be classified into several categorie: presence
of defective sperm, varicocele and chronic prostatitis,
smoking, drug abuse like marijuana (social causes),
alcohol, exposure to irritants and toxins, use of vaginal
products by partner during sexual activities, abstinence,
vasovasostomy, clomiphene citrate therapy, and urethroplasty,
Chlamydia Trachomatis, Gardnerella
vaginalis and Ureaplasma urealyticum, in patients' sexual partners (genital
infection), lower CD4+ cell counts in HIV
patients. Apart from the diverse etiologies, many other causes have been
drawn from various clinical researches in recent years.
In 1995, Matthews et al. [15] described that clomiphene
citrate-treated men (over the age of 35) are more likely
to develop pyospermia when they are treated with
nonbacterial drug therapy, which may adversely impact male
fertility. Anderson [10] suggested that pyospermia is
associated with subclinical genital tract infection.
However, current research studies failed to recognize
any specific bacterial pathogens in semen that are
responsible for the disease. In addition, with the
widespread prevalence of AIDS, a potential association
between a low CD4+ cell count in HIV patients with
pyospermia and other presentations of sperm
abnormalities has been reported [16].
4 Pathogenesis
To understand the pathological pathways of
pyospermia, the exact roles and types of WBCs should be
delineated. There are three main categories of WBCs
that can be morphologically distinguished: granulocytes,
monocytes and lymphocytes. Granulocytes can be
further subdivided into neutrophils, eosinophils and basophils.
Under a normal human defensive response to invasion
by foreign matters, WBCs would accumulate in the
infected area. Neutrophil, which is the predominant
granulocyte subtype, specifically invades the lipid membrane
of the pathogens by releasing reactive oxygen species
(ROS).
ROS is the specific class of oxygen free radicals that
are responsible for damaging the lipid components of the
sperm membrane [17]. ROS is the highly reactive
oxidizing agents that are also produced by defective
spermatozoa in vivo in addition to the granulocytes [18_20].
ROS is also produced by the sperm from a variety of
diseases such as vasectomy reversal, varicocele and
idiopathic infertility, besides the leukocytes
[21]. Hydrogen peroxide
(H2O2) is the most potent species among all
types of ROS. There are also other species of ROS
such as nitric oxide radicals (NO-), peroxynitrite anion
(ONOO_), superoxide (O2_), and hydroxyl
(OH_) that exhibit the same effects [20, 22, 23].
Spermatozoa contain the genetic material and are
surrounded by a double-layered membrane. This membrane
is composed of lipid and protein just like the normal
plasma membrane. The lipid portion of this membrane
consists of a special phospholipid, Plasmalogen, and a
substantial concentration of polyunsaturated fatty acids
(PUFA), which play an important role in the
development of pyospermia. When spermatozoa are invaded by
the surrounding ROS (oxidative stress), the lipids that
are exposed on the sperm's membrane become the specific targeting sites of ROS [20, 24].
Intrinsically, the pathophysiological pathway of
ROS-induced deleterious spermatozoa effects can be explained
through a mechanism named lipid peroxidation (LPO)
[25]. In any event in response to infection, inflammatory,
or autoimmune activities, ROS production by WBCs will
be triggered through the LPO mechanism. LPO is
initiated when the sperm membrane is attacked by ROS.
After the successful entrance through the spermatic
membranes, ROS will proceed to penetrate further where
all the genetic materials are located. On the molecular
level, once ROS invade the sperm, they destroy the
mitochondrial DNA and thus disrupt the intracellular ATP
production in spermatozoa [24, 26]. With the decreased
production of ATP, energy for the sperm activities,
motility and other functions will be lost.
The modulation of ROS production in seminal plasma
is equilibrated between the pro-oxidant and anti-oxidant
activities [24, 27]. Pro-oxidant activity (pro-infertility),
which is sperm hostile, is the action that generates ROS,
which decreases sperm activity and function through the
LPO mechanism. Anti-oxidant activity (pro-fertility) is
sperm friendly and is the action that scavenges the ROS.
This activity is maintained by the presence of a
significant level of antioxidants, such as the enzyme
superoxide dismutase (SOD), catalase, urate, sulphydryl groups,
tocopherol (vitamin E), vitamin C (ascorbate) and
carotenoids [27_30]. These anti-oxidants directly target the
ROS activities or LPO mechanism. They protect the
sperm membrane and spermatic DNA structures and prevent them from destruction under oxidative stress
triggered by ROS [28].
Glutathione peroxidase (GSH) is another antioxidant
enzyme, which specifically acts on eliminating various
ROS such as hydrogen peroxides. While undergoing this activity, GSH is converted into its inactive form,
glutathione disulfide (GSSG). In order to resume its active
form, NADPH is needed. One of the modern diagnostic
modalities in pyospermia is to determine the GSH/GSSG
ratio. The high ratio indicates that more GSH is present
in vivo to counteract the peroxidase activities by the
peroxides [31, 32].
Without the inhibitory presence of ROS, sperm
resumes its normal activities. A positive oxidative stress
status (OSS) is the term used to denote the increased
level of ROS production towards pro-oxidants in semen
and the decrease in antioxidant activities, the antagonist
of ROS and vice versa [33]. The balancing mechanisms
between pro- and anti-oxidants in regulating the effect
of WBCs on sperm are presented in Figure 1.
Besides the contribution of positive OSS by the ROS
activities, Sikka [32] reported that production of
chemokines such as IL-8 and GROα, in response to
infection and inflammation, may also contribute to the
positive oxidative stress status and further decrease motility
and other functions of sperms and thus categorize them
as the pro-inflammatory substances. However, IL-10 is
the other chemokine that acts as anti-inflammatory
substance. The two types of chemokines, like the
balances between ROS and SOD, demonstrate the
counterbalance phenomenon for the determination of disease states.
5 Investigations
Pyospermia is considered to be one of the causes of
male infertility [34]. Shy et
al. [12] demonstrated an association between the presence of leukocytes in
semen and the subsequent decreased pregnancy rates. With
these statistical data in mind, investigations should be
comprehensive. A current clinical investigation should
ideally include determination of the couple's history of
infertility, their sexual habits, the spouse's primary and
secondary sexual characteristics, and medical, genetic,
surgical, family history, exposure to gonadotoxins and a
thorough review of systems. Laboratory testings include
differential sperm separation method, endocrine evaluation, semen analysis, and if indicated, culture of
the ejaculates, quantitation of leukocytes in semen,
antisperm antibodies and immature germ cells in semen
[4, 35, 36]. An important factor to be considered is that
the short half life of polymorphonuclear neutrophils
(PMN) in semen makes them a major source for factors
that can be harmful to sperms. PMN have also been
shown to be activated by sperm cells resulting in
formation of neutrophil extracellular traps that trap sperm [24].
Evaluation of pyospermic patients comprises a
focused history and physical examination, examination of
prostatic fluid, semen analysis and ultrasound imaging
of the accessory sex glands, ejaculatory duct, and lower
urinary tract. There are various techniques for detection
of pyospermia in human semen. Persistent pyospermia,
which is pyospermia observed in semen specimens
collected at 3-month interval, is an indication for repeat
physical and microbiological examination of semen after which
empiric antibiotic treatment can be initiated [37].
Immounocytological method is the most recent
laboratory technique that uses monoclonal antibodies as
labels and is the best method for distinguishing leukocytes
in semen. This method, however, is too expensive and
time-consuming to be used on a routine basis. It is rather
more applicable in a research setting. The Bryan-Leishman
stain is used in many studies and is a useful method of
identifying total leukocytes per 100 sperm. The number
of WBCs per 100 sperm is usually counted on a direct
semen smear stained by the Bryan-Leishman method of
Couture and it also allows differentiating leukocytes from
immature sperm cells [38]. But this stain is not used
widely because it takes 2_2.5 h, and requires about
20_30 min to accurately prepare multiple slides for
examination. This technique of measuring leukocytes per 100
sperm gives accurate measurements when sperm counts
are normal but overestimates leukocyte numbers in oligozoospermic men. Monoclonal antibodies facilitate
accurate counts but are time-consuming and expensive
to be used on a routine basis.
Shekarriz et al. [39] in their evaluation of semen by
Endtz test showed the presence of irregular quantity of
ROS accumulation in semen, so as to indicate the
presence of pyospermia. The level of elastase present in
seminal plasma has been shown to bear a direct
relationship to pyospermia [40]. Elastase is an enzyme acting as
distinct marker of inflammation. Its level correlates with
the amount of WBC presented in semen, so that the
degree of inflammation can be ascertained [40]. IL-6 and
granulocyte elastase are also found to be useful and
suitable markers for silent genital tract inflammation [41].
6 Differential diagnosis
The differential diagnosis of symptomatic pyospermia
includes infection, autoimmune disease, and
inflammation of accessory sex glands and lower male urogenital
tract. Urogenital infections include acute and chronic
prostatitis, seminal vesiculitis, epididymo-orchitis, cystitis,
urethritis, urethral stricture, stone disease, foreign bodies,
upper urinary tract infection, retrograde ejaculation, and
localized sepsis of the adjacent lower gastro-intestinal
tract and asymptomatic bacteriuria. The chronic
infections that may result in pyospermia include fungal,
mycobacterial, congenital lesions causing infection of the
urogenital tract. Refractory autoimmune diseases that
afflict the urogenital tract include Behcet's syndrome and
Reiter's disease.
7 Management
There is no definite medical management of pyospermia because the specific causes of the disease
cannot be isolated (Figure 2). The current management
methodology surrounds elimination of the cause (if any),
correction of predisposing factors, elimination of
infection and protection from free radicals and oxidative agents
produced inside the body as a result of inflammation,
infection, or auto-immunity. The treatment options can
be categorized into antibiotics treatment (doxycycline,
trimethoprim and sulfamethoxazole, ofloxacin),
medications such as calcium dobesilate, propofol, rebamipide,
N-acetyl-L-Cysteine (NAC), glutathione, coenzyme ubiquinol-10 (CoQ10), ferulic acid (FA), and vitamin C
and E (α-tocopherol). Other alternative treatments
include Chinese herbs (Magnolol), natural product antioxidants, and the practice of frequent ejaculation
[42_49].
The removal of cause and primary predisposing
factors include the correction of any congenital or acquired
defect in the genitourinary tract harboring infection and
inflammation, vesicourethral reflux, prostatic
obstruction and infection, retrograde ejaculation, and urethral
valves. These modalities follow the mechanism that
scavenges ROS with the inhibition of LPO, such as
coenzymes ubiquinol-10 [50, 51].
Several clinical trials have investigated the efficacy
of antibiotic therapy to treat patients with pyospermia in
an attempt to improve fertility. Many studies have
reported a decrease in seminal WBC concentration and
improved sperm function following a course of
antibiotics [52_54]. However, large clinical trials reported no
significant beneficial effect of either doxycycline or
Bactrim therapy because of a high rate of spontaneous
resolution in untreated leuko-cytospermic men [55, 56].
By studying the efficacy of doxycycline and the
combination of doxycycline with ceftriaxone for the treatment
of asymptomatic men with pyospermia, it was disco-vered that antibiotic therapy is not beneficial for
asymptomatic men with pyospermia [57]. Because of the risk
factors associated with antibiotic therapy like their
relative toxicity and the mechanisms by which antibiotics
affect spermatogenesis and spermatozoa function [58],
it would be important in the future to design a study that
includes a WBC enumeration assay, which will allow one
to differentiate between chronic and acute pyospermia
and positively diagnose bacterial infections by culture or
molecular biology technique before the initiation of
therapy.
Other therapies have been proposed for the
treatment of genital tract inflammation associated with
pyospermia. Clinical trials are presently underway with
vitamin E (α-tocopherol) which acts as an anti-oxidant
in patients with a high concentration of free radical
levels in their semen by reducing the lipid peroxidation
activities in vitro in human spermatozoa [59_62]. Recently
Akiyama [63] reported that the administration of ethylcysteine and tocopherol (vitamin E) resulted in
significant improvement in sperm function but there was
no statistically significant effect on sperm density or
motility. The author also reported significantly reduced
level of ROS after the administration of ethylcysteine [63].
In addition, pentoxifylline has been used recently to
enhance sperm motility in severely oligospermic and
asthenospermic men [64, 65]. It decreases ROS generation by spermatozoa and thus increases the
anti-oxidant activities in vitro [64, 66]. Other treatments, such
as administering glutathione in vivo, showed
improvement in the function of spermatozoa [67]. Because there
are no multi-institutional fertility studies, it is unknown if
male infertility can be improved. The diagnosis of
pyospermia is usually based on the levels of leukocytes
in semen but controversy remains over the
minimum leukocyte level that impairs fertility. ROS can be found
even in patients with very low seminal WBC counts and
rises with an increase in WBC count. Therefore, it is
relatively difficult to determine a safe minimum WBC
count (as per WHO guidelines) as the presence of any
WBC is associated with ROS, which damages semen quality and may
therefore impair fertility [68].
8 Conclusion
Further researches are needed in this area because
the methods for enumerating leukocytes and
characterizing their products are not standardized. Also, the exact
role of WBCs, their products and subtypes (i.e. neutrophils, lymphocytes, monocytes, eosinophils and
basophils) in the male reproductive tract, is not clear.
Moreover, the exact role of infections, especially
sexually transmitted viral infections of the male genital tract,
in causing pyospermia is unknown. There have been
significant advances in the medical treatment of pyospermia in recent years
[69_72], especially that with anti-oxidant agents. Further research is needed to
explore the efficacy of various anti-viral,
immunosuppressive and current anti-inflammatory drugs in the
treatment and prevention of pyospermia. So far, evidence
seems to indicate that progress has been made with
regard to the understanding of pathophysiological
mechanisms involved in damaging spermatozoa in patients with
significantly high amounts of leukocytes in the semen.
Nonetheless, research should continue to exactly
identify the intensity and nature of damage caused by
various leukocytic subtypes and their products.
References
1 Aitken RJ. A free radical theory of male infertility. Reprod
Fertil Dev 1994; 6: 19_24.
2 Barratt CL, Bolton AE, Cooke ID. Functional significance of
white blood cells in the male and female reproductive tract.
Hum Reprod 1990; 5: 639_48.
3 Wolff H, Anderson DJ. Immunohistologic characterization
and quantitation of leucocyte subpopulation in human semen.
Fertil Steril 1988; 49: 497_504.
4 Arata de Bellabarba G, Tortolero I, Villarroel V, Molina CZ,
Bellabarba C, Velazquez E. Nonsperm cells in human semen
and their relationship with semen parameters. Arch Androl
2000; 45: 131_6.
5 Eisermann J, Register KB, Strickler RC, Collins JL. The effect
of tumor necrosis factor on human sperm motility
in vitro. J Androl 1988; 10: 270_4.
6 Lackner JE, Herwig R, Schmidbauer J, Schatzl G, Kratzik C,
Marberger M. Correlation of leukocytospermia with clinical
infection and the positive effect of antiinflammatory
treatment on semen quality. Fertil Steril 2006; 86: 601_5.
7 Wolff H, Politch JA, Martinez A, Haimovici F, Hill JA,
Anderson DJ. Leukocytospermia is associated with poor semen
quality. Fertil Steril 1990; 53: 528_36.
8 Berger RE, Karp LE, Williamson RA, Koechler J, Moore DE,
Holmes KK. The relationship of pyospermia and seminal
fluid bacteriology to sperm function as reflected in the sperm
penetration assay. Fertil Steril 1982; 37: 557_64.
9 Maruyama DK Jr, Hale RW, Rogers BJ. Effects of white
blood cells on the in vitro penetration of zona-free hamster
eggs by human spermatozoa. J Androl 1985; 6: 127_35.
10 Anderson DJ. Should male patients be tested for
leukocytospermia? Fertil Steril 1995; 63: 246_8.
11 Sigman M, Lopes L. The correlation between round cells and white
blood cells in the semen. J Urol 1993; 149 (5 Pt 2): 1338_40.
12 Shy KK, Stenchever MA, Muller CH. Sperm penetration
assay and subsequent pregnancy: a prospective study of 74
infertile men. Obstet Gynecol 1988; 71: 685_90.
13 World Health Organization. WHO Semen Manual for the
Examination of Human Semen and Cervical Mucus. Cambridge:
Cambridge University Press, 1992; p8_11.
14 Branigan EF, Spadoni LR, Muller CH. Identification and
treatment of leukocytospermia in couples with unexplained
infertility. J Reprod Med 1995; 40: 625_9.
15 Matthews GJ, Goldstein M, Henry JM, Schlegel PN.
Nonbacterial pyospermia: a consequence of clomiphene citrate
therapy. Int J Fertil Menopausal Stud 1995; 40: 187_91.
16 Muller CH, Coombs RW, Krieger JN. Effects of clinical stage
and immunological status on semen analysis results in human
immunodeficiency virus type 1-seropositive men. Andrologia
1998; 30: 15_22.
17 Sharma RK, Agarwal A. Role of reactive oxygen species in
male infertility. Urology 1996; 48: 835_50.
18 Dolganiuc A, Radu D, Olinescu A, Vrabiescu, A. Procain and
diethylaminoethanol influence on the release of free oxygen
radicals by polymorphonuclear leukocytes, in rabbits and
humans. Roum Arch Microbiol Immunol 1998; 57: 23_32.
19 Iwasaki A, Gagnon C. Formation of reactive oxygen species in
spermatozoa of infertile patients. Fertil Steril 1992; 7: 409_16.
20 Gagnon C, Iwasaki A, de Lamirande E, Kovalski N. Reactive
oxygen species and human spermatozoa. Ann N Y Acad Sci
1991; 637: 436_44.
21 Pasqualotto FF, Sharma RK, Nelson DR, Thomas AJ, Agarwal
A. Relationship between oxidative stress, semen
characteristics and clinical diagnosis in men undergoing infertility
investigation. Fertil Steril 2000; 73: 459_64.
22 Nobunaga T, Tokugawa Y, Hashimoto K, Kubota Y, Sawai K,
Kimura T, et al. Elevated nitric oxide concentration in the
seminal plasma of infertile males: nitric oxide inhibits sperm
motility. Am J Reprod Immunol 1996; 36: 193_7.
23 Rosselli M, Dubey RK, Imthurn B, Macas E, Keller PJ.
Effects of nitric oxide on human spermatozoa: evidence that
nitric oxide decreases sperm motility and induces sperm
toxicity. Hum Reprod 1995; 10: 1786_90.
24 Villegas J, Schulz M, Soto L, Iglesias T, Miska W, Sanchez R.
Influence of reactive oxygen species produced by activated
leukocytes at the level of apoptosis in mature human
spermatozoa. Fertil Steril 2005; 83: 808_10.
25 Ernster L. Lipid peroxidation in biological membranes:
mechanisms and implications. In: Yagi K, editor. Active Oxygen,
Lipid Peroxides and Antioxidants. Boca Raton: CRC Press,
1993; p1_38.
26 de Lamirande E, Gagnon C. Reactive oxygen species and
human spermatozoa. I. Effects on the motility of intact
spermatozoa and on sperm axonemes; and II. Depletion of
adenosine triphosphate plays an important role in the inhibition of
sperm motility. J Androl 1992; 13: 368_86.
27 Sikka SC, Rajasekaran M, Hellstrom WJ. Role of oxidative stress
and antioxidants in male infertility. J Androl 1995; 16:464_8.
28 Alvarez JG, Touchstone JC, Blasco L, Storey BT.
Spontaneous lipid peroxidation and production of hydrogen peroxide
and superoxide in human spermatozoa. Superoxide dismutase
as major enzyme protectant against oxygen toxicity. J Androl
1987; 8:338_48.
29 Lewis SE, Sterling ES, Young IS, Thompson W. Comparison
of individual antioxidants of sperm and seminal plasma in
fertile and infertile men. Fertil Steril 1997; 67: 142_7.
30 Smith R, Vantman D, Ponce J, Escobar J, Lissi E. Total
antioxidant capacity of human seminal plasma. Hum Reprod
1996; 11: 1655_60.
31 Ford WC, Whittington K, Williams AC. Reactive oxygen
species in human sperm suspensions: production by
leukocytes and the generation of NADPH to protect sperm against
their effects. Int J Androl 1997; 20 (Suppl 3): 44_9.
32 Sikka SC. Oxidative stress and role of antioxidants in normal
and abnormal sperm function. Front Biosci 1996; 1: 78_86.
33 Cummins JM, Jequier AM, Raymond K. Molecular biology of
human male infertility: links with aging, mitochondrial genetics,
and oxidative stress? Mol Reprod Dev 1994; 37: 345_62.
34 Branigan EF, Muller CH. Efficacy of treatment and
recurrence rate of leukocytospermia in infertile men with prostatitis.
Fertil Steril 1994; 62: 580_4.
35 Henkel R, Maass G, Hajimohammad M, Menkveld R, Stalf T,
Villegas J, et al. Urogenital inflammation: changes of leucocytes
and ROS. Andrologia 2003; 35: 309_13.
36 Fisch H, Lipshultz LI. Diagnosing male factors of infertility.
Arch Pathol Lab Med 1996; 116: 398_405.
37 Fedder J. Nonsperm cells in human semen: with special
reference to seminal leukocytes and their possible influence on
fertility. Arch Androl 1996; 36: 41_65.
38 Couture M, Ulstein M, Leonard J, Paulsen CA.
Improved-staining method for differentiating immature germ cells from white
blood cells in human seminal fluid. Andrologia 1976; 8: 61_6.
39 Shekarriz M, Thomas AJ Jr, Agarwal A. Incidence and level of
seminal reactive oxygen species in normal men. Urology 1995;
45: 103_7.
40 Micic S, Macura M, Lalic N, Dotlic R. Elastase as an indicator
of silent genital tract infection in infertile men. Int J Androl
1989; 12: 423_9.
41 Kopa Z, Wenzel J, Papp GK, Haidl G. Role of granulocyte
elastase and interleukin-6 in the diagnosis of male genital tract
inflammation. Andrologia 2005; 37: 188_94.
42 Brunet J, Farine JC, Garay RP, Hannaert P.
In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol
1998; 12: 205_12.
43 Henkel R, Schill WB. Sperm separation in patients with
urogenital infections. Andrologia 1998; 30: 91_7.
44 Iinuma S, Naito Y, Yoshikawa T, Takahashi S, Takemura T,
Yoshida N, et al. In vitro studies indicating antioxidative
properties of rebamipide. Dig Dis Sci 1998; 43 (Suppl): 35S_39S.
45 Kosiec T, Marianowski L, Meisel-Mikolajczyk F, Rekosz A.
Results of treatment with ofloxacin for inflammatory
conditions in male reporductive organs. Wiad Lek 1992; 45: 827_9.
46 Lin MH, Chao HT, Hong CY. Magnolol protects human
sperm motility against lipid peroxidation: a sperm head
fixation method. Arch Androl 1995; 34: 151_6.
47 Mikawa K, Akamatsu H, Nishina K, Shiga M, Maekawa N,
Obara H, et al. Propofol inhibits human neutrophil functions.
Anesth Analg 1998; 87: 695_700.
48 Oeda T, Henkel R, Ohmori H, Schill WB. Scavenging effect of
N-acetyl-L-cysteine against reactive oxygen species in human
semen: a possible therapeutic modality for male factor
infertility? Andrologia 1997; 29: 125_31.
49 Zheng RL, Zhang H. Effects of ferulic acid on fertile and
asthenozoospermic infertile human sperm motility, viability,
lipid peroxidation, and cyclic nucleotides. Free Radic Biol
Med 1997; 22: 581_6.
50 Alleva R, Scararmucci A, Mantero F, Bompadre S, Leoni L,
Littarru GP. The protective role of ubiquinol-10 against
formation of lipid hydroperoxides in human seminal fluid. Mol
Aspects Med 1997; 18 (Suppl): S221_8.
51 Lewin A, Lavon H. The effect of coenzyme Q10 on sperm motility
and function. Mol Aspects Med 1997; 18 (Suppl): S213_9.
52 Berger RE, Smith WD, Critchlow CW, Stenchever MA, Moore
DE, Spadoni LR, et al. Improvement in the sperm penetation
(hamster ova) assay (SPA) results after doxycycline treatment
of infertile men. J Androl 1983; 4: 126_36.
53 Harrison RF, de Louvois J, Blades M, Hurley R. Doxycycline
treatment and human infertility. Lancet 1975; 1: 605_7.
54 Matthews CD, Clapp KH, Tansing JA, Cox LW.
T-mycoplasma genital infection, the effect of doxycycline therapy on
human unexplained infertility. Fertil Steril 1978; 30: 98_9.
55 Yamamoto M, Hibi H, Katsuno S, Miyake K. Antibiotic and
ejaculation treatments improve resolution rate of leukocytospermia in
infertile men with prostatitis. Nagoya J Med Sci 1995; 58: 41_5.
56 Yanushpolsky EH, Politch JA, Hill JA, Anderson DJ.
Antibiotic therapy and leukocytospermia: a prospective, randomized,
controlled study. Fertil Steril 1995; 63: 142_7.
57 Erel CT, Senturk LM, Demir F, Irez T, Ertungealp E.
Antibiotic therapy in men with leukocytospermia. Int J Fertil
Womens Med 1991; 42: 206_10.
58 Schlegel PN, Chong TS, Marshall FF. Antibiotics: potential
hazards to male fertility. Fertil Steril 1991; 55: 235_42.
59 Geva E, Bartoov B, Zabludovsky N, Lessing JB, Lerner-Geva
L, Amit A. The effect of antioxidant treatment on human
spermatozoa and fertilization rate in an in
vitro fertilization program. Fertil Steril 1996; 66: 430_4.
60 Kessopoulou E, Powers HJ, Sharma KK, Pearson MJ, Russell
JM, Cooke ID, et al. A double-blind randomized placebo
cross-over controlled trial using the antioxidant vitamin E to
treat reactive oxygen species associated male infertility. Fertil
Steril 1995; 64: 825_31.
61 Suleiman SA, Ali ME, Zaki ZM, el-Malik EM, Nasr MA.
Lipid peroxidation and human sperm motility: protective role
of vitamin E. J Androl 1996; 17: 530_7.
62 Therond P, Auger J, Legrand A, Jouannet P.
Alpha-Tocopherol in human spermatozoa and seminal plasma:
relationships with motility, antioxidant enzymes and leukocytes. Mol
Hum Reprod 1996; 2: 739_44.
63 Akiyama M. In vivo scavenging effect of ethylcysteine on
reactive oxygen species in human semen. Nippon Hinyokika
Gakkai Zasshi 1999; 90: 421_8.
64 Okada H, Tatsumi N, Kanzaki M, Fujisawa M, Arakawa S,
Kamidono S. Formation of reactive oxygen species by
spermatozoa from asthenospermic patients: response to treatment
with pentoxifylline. J Urol 1997; 157: 2140_6.
65 Sikka SC, Hellstrom WJG, Naz RK. Pentoxifylline: role in
management of male infertility/mechanisms of action. Molecu
Androl 1993; 5: 220_31.
66 Nguyen P, Broussas M, Hezard N, Cornillet P, Potron G.
Modulators of leukocytic functions. J Mal Vasc 1998; 23: 119_24.
67 Irvine DS. Glutathione as a treatment for male infertility. Rev
Reprod 1996; 1: 6_12.
68 Sharma RK, Pasqualotto AE, Nelson DR, Thomas AJ, Agarwal
A. Relationship between seminal white blood cell counts and
oxidative stress in men treated at an infertility clinic. J Androl
2001; 22: 575_83.
69 Zalata AA, Ahmed AH, Allamaneni SS, Comhaire FH, Agarwal
A. Relationship between acrosin activity of human
spermatozoa and oxidative stress. Asian J Androl 2004; 6: 313_8.
70 Li J, Liu RZ. Progresss in leukocytospermia research.
Zhonghua Nan Ke Xue 2006; 12: 730_2, 736.
71 Sheweita SA, Tilmisany AM, Al-Sawaf H. Mechanisms of male
infertility: Role of antioxidants. Curr Drug Metab 2005; 6: 495_501.
72 Oliva A, Multigner L. Ketotifen improves sperm motility and
sperm morphology in male patients with leukocytospermia
and unexplained infertility. Fertil Steril 2006; 85: 240_3.
|